Befragung von Hausärzt*innen zur Versorgung von Patienten unter oralen Tyrosinkinaseinhibitoren

Florian Kaiser(University of Applied Sciences Landshut), Ulrich Kaiser(University of Applied Sciences Landshut), Ana Hoffmann(University of Applied Sciences Landshut), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Felix Kaiser(Universitätsmedizin Göttingen), Xenia Schulz(University of Applied Sciences Landshut)
Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen
November 13, 2020
10.1016/j.zefq.2020.08.003
Cited by 2

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
|The Lancet Oncology|2016|417
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
|Annals of Oncology|2006|280